Influence of clozapine on platelet serotonin, monoamine oxidase and plasma serotonin levels

Ertuğrul, Aygün; Uçar, Gülberk; Başar, Koray; Demir, Başaran; Yabanoglu, Samiye; Uluğ, Berna

doi:10.1016/j.psychres.2005.12.009

Cited by 34 publications

(28 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Purdon et al (32) reported significant improvement in verbal learning and memory after treatment with clozapine. Their results were not replicated by Ertugrul et al (33) and Sumiyoshi et al (34) as both of these studies did not find improvement in verbal memory in clozapine-treated patients. This discrepancy in findings could be due to methodological differences such as different test batteries and trial duration.…”

Section: Verbal Learning and Memorymentioning

confidence: 79%

Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What’s the Evidence?

et al. 2013

View full text Add to dashboard Cite

Schizophrenia is a disabling, chronic psychiatric disorder with a prevalence rate of 0.5–1% in the general population. Symptoms include positive (e.g., delusions, hallucinations), negative (e.g., blunted affect, social withdrawal), as well as cognitive symptoms (e.g., memory and attention problems). Although 75–85% of patients with schizophrenia report cognitive impairments, the underlying neuropharmacological mechanisms are not well understood and currently no effective treatment is available for these impairments. This has led to the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative, which established seven cognitive domains that are fundamentally impaired in schizophrenia. These domains include verbal learning and memory, visual learning and memory, working memory, attention and vigilance, processing speed, reasoning and problem solving, and social cognition. Recently, a growing number of studies have been conducted trying to identify the underlying neuropharmacological mechanisms of cognitive impairments in schizophrenia patients. Specific cognitive impairments seem to arise from different underlying neuropharmacological mechanisms. However, most review articles describe cognition in general and an overview of the mechanisms involved in these seven separate cognitive domains is currently lacking. Therefore, we reviewed the underlying neuropharmacological mechanisms focusing on the domains as established by the MATRICS initiative which are considered most crucial in schizophrenia.

show abstract

Section: Verbal Learning and Memorymentioning

confidence: 79%

Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What’s the Evidence?

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The increase in peripheral 5-HT concentrations reported in the early studies was apparently not an artifact of medication, as no in vivo effect of antipsychotics on platelet 5-HT could be demonstrated (Bleich et al, 1991). On the contrary, accumulating evidence suggests that treatment with clozapine and other atypical and typical antipsychotics increases 5-HT plasma levels in schizophrenia patients (Joseph et al, 1977;Schulz et al, 1997;Fleischhaker et al, 1998;van der Heijden et al, 2004;Ertugrul et al, 2007). These findings suggest that antipsychotics still have an impact on peripheral 5-HT concentrations and indicate that medication may have indeed influenced previous results.…”

Section: Platelet Studiesmentioning

confidence: 95%

“…Although there are some indications of decreased platelet MAO activity at least in some subgroups of schizophrenia patients (Zureick and Meltzer, 1988), it could not be excluded that this effect is primarily caused by antipsychotic treatment (DeLisi et al, 1981;Ohuoha et al, 1993;Ertugrul et al, 2007).…”

Section: Platelet Studiesmentioning

confidence: 99%

Serotonin and Schizophrenia

Quednow

Geyer

Halberstadt

2010

Handbook of Behavioral Neuroscience

View full text Add to dashboard Cite

Although the serotonin hypothesis of schizophrenia is one of the oldest neurochemical hypotheses on the pathogenesis of this disease, it is still highly topical. The concept of how the serotonin system is involved in the origin and progress of schizophrenia has considerably changed over the past decades. Therefore, the present work will give an overview about the development and the current directions of the serotonin hypothesis of schizophrenia. In this regard, we will discuss the phenomenology of hallucinogenic drug action, model psychosis and translational research, post-mortem studies on receptors and transporters, imaging studies, antipsychotic drug action, neuroendocrine challenge studies, platelet and cerebrospinal fluid data, genetic association studies, developmental aspects, and the cross-talk between the glutamate and the serotonin system. In sum, there are several lines of evidence suggesting that the serotonin system plays a major role in the pathogenesis of at least a subpopulation of schizophrenia patients. Further studies are needed to better characterize patients whose psychotic symptoms are suspected to have a serotonergic origin. Serotonin and Schizophrenia AbstractAlthough the serotonin hypothesis of schizophrenia is one of the oldest neurochemical hypotheses on the pathogenesis of this disease, it is still highly topical. The concept of how the serotonin system is involved in the origin and progress of schizophrenia has considerably changed over the past decades.Therefore, the present work will give an overview about the development and the current directions of the serotonin hypothesis of schizophrenia. In this regard, we will discuss the phenomenology of hallucinogenic drug action, model psychosis and translational research, post-mortem studies on receptors and transporters, imaging studies, antipsychotic drug action, neuroendocrine challenge studies, platelet and cerebrospinal fluid data, genetic association studies, developmental aspects, and the cross-talk between the glutamate and the serotonin system. In sum, there are several lines of evidence suggesting that the serotonin system plays a major role in the pathogenesis of at least a subpopulation of schizophrenia patients. Further studies are needed to better characterize patients whose psychotic symptoms are suspected to have a serotonergic origin.3

show abstract

“…It is widely considered to be a contributor to feelings of well-being and happiness (Ertugrul et al, 2007). Serotonin plays an important role in psychiatric disorders like depression, anxiety and Parkinson's disease.…”

Section: Introductionmentioning

confidence: 99%

miR-16 and Fluoxetine Both Reverse Autophagic and Apoptotic Change in Chronic Unpredictable Mild Stress Model Rats

Yang

et al. 2017

Front. Neurosci.

View full text Add to dashboard Cite

In the clinic selective serotonin reuptake inhibitors (SSRIs), like Fluoxetine, remain the primary treatment for major depression. It has been suggested that miR-16 regulates serotonin transporters (SERT) via raphe nuclei and hippocampal responses to antidepressants. However, the underlying mechanism and regulatory pathways are still obtuse. Here, a chronic unpredicted mild stress (CUMS) depression model in rats was established, and then raphe nuclei miR-16 and intragastric Fluoxetine injections were administered for a duration of 3 weeks. An open field test and sucrose preference quantification displayed a significant decrease in the CUMS groups when compare to the control groups, however these changes were attenuated by both miR-16 and Fluoxetine treatments. A dual-luciferase reporter assay system verified that hsa-miR-16 inhibitory effects involve the targeting of 3′UTR on the 5-HTT gene. Expression levels of miR-16 and BDNF in the hippocampus were examined with RT-PCR, and it was found that increased 5-HT2a receptor expression induced by CUMS can be decreased by miR-16 and Fluoxetine administration. Immunofluorescence showed that expression levels of neuron NeuN and MAP-2 in CUMS rats were lower. Apoptosis and autophagy levels were evaluated separately through relative expression of Bcl-2, Caspase-3, Beclin-1, and LC3II. Furthermore, CUMS was found to decrease levels of hippocampal mTOR, PI3K, and AKT. These findings indicate that apoptosis and autophagy related pathways could be involved in the effectiveness of antidepressants, in which miR-16 participates in the regulation of, and is likely to help integrate rapid therapeutic strategies to alleviate depression clinically. These findings indicate that miR-16 participates in the regulation of apoptosis and autophagy and could account for some part of the therapeutic effect of SSRIs. This discovery has the potential to further the understanding of SSRIs and accelerate the development of new treatments for depression.

show abstract

Influence of clozapine on platelet serotonin, monoamine oxidase and plasma serotonin levels

Cited by 34 publications

References 41 publications

Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What’s the Evidence?

Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What’s the Evidence?

Serotonin and Schizophrenia

miR-16 and Fluoxetine Both Reverse Autophagic and Apoptotic Change in Chronic Unpredictable Mild Stress Model Rats

Contact Info

Product

Resources

About